These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 21183486)

  • 1. Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.
    Picconi B; Bagetta V; Ghiglieri V; Paillè V; Di Filippo M; Pendolino V; Tozzi A; Giampà C; Fusco FR; Sgobio C; Calabresi P
    Brain; 2011 Feb; 134(Pt 2):375-87. PubMed ID: 21183486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
    Picconi B; Paillé V; Ghiglieri V; Bagetta V; Barone I; Lindgren HS; Bernardi G; Angela Cenci M; Calabresi P
    Neurobiol Dis; 2008 Feb; 29(2):327-35. PubMed ID: 17997101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms.
    Giorgi M; D'Angelo V; Esposito Z; Nuccetelli V; Sorge R; Martorana A; Stefani A; Bernardi G; Sancesario G
    Eur J Neurosci; 2008 Sep; 28(5):941-50. PubMed ID: 18717735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
    Carta M; Lindgren HS; Lundblad M; Stancampiano R; Fadda F; Cenci MA
    J Neurochem; 2006 Mar; 96(6):1718-27. PubMed ID: 16539687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia.
    Ueno T; Yamada J; Nishijima H; Arai A; Migita K; Baba M; Ueno S; Tomiyama M
    Neurobiol Dis; 2014 Apr; 64():142-9. PubMed ID: 24398173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?
    Calabresi P; Giacomini P; Centonze D; Bernardi G
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S60-8; discussion S68-9. PubMed ID: 10762133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia.
    Cerovic M; Bagetta V; Pendolino V; Ghiglieri V; Fasano S; Morella I; Hardingham N; Heuer A; Papale A; Marchisella F; Giampà C; Calabresi P; Picconi B; Brambilla R
    Biol Psychiatry; 2015 Jan; 77(2):106-15. PubMed ID: 24844602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms.
    Ghiglieri V; Mineo D; Vannelli A; Cacace F; Mancini M; Pendolino V; Napolitano F; di Maio A; Mellone M; Stanic J; Tronci E; Fidalgo C; Stancampiano R; Carta M; Calabresi P; Gardoni F; Usiello A; Picconi B
    Neurobiol Dis; 2016 Feb; 86():140-53. PubMed ID: 26639853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal bidirectional plasticity-like effects in Parkinson's disease.
    Huang YZ; Rothwell JC; Lu CS; Chuang WL; Chen RS
    Brain; 2011 Aug; 134(Pt 8):2312-20. PubMed ID: 21742734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A critical role of the nitric oxide/cGMP pathway in corticostriatal long-term depression.
    Calabresi P; Gubellini P; Centonze D; Sancesario G; Morello M; Giorgi M; Pisani A; Bernardi G
    J Neurosci; 1999 Apr; 19(7):2489-99. PubMed ID: 10087063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Buck K; Ferger B
    Synapse; 2010 Feb; 64(2):117-26. PubMed ID: 19771592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
    Buck K; Ferger B
    Neuroscience; 2009 Mar; 159(1):16-20. PubMed ID: 19146929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat.
    Lebel M; Chagniel L; Bureau G; Cyr M
    Neurobiol Dis; 2010 Apr; 38(1):59-67. PubMed ID: 20060905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A positive allosteric modulator of mGlu4 receptors restores striatal plasticity in an animal model of l-Dopa-induced dyskinesia.
    Calabrese V; Picconi B; Heck N; Campanelli F; Natale G; Marino G; Sciaccaluga M; Ghiglieri V; Tozzi A; Anceaume E; Cuoc E; Caboche J; Conquet F; Calabresi P; Charvin D
    Neuropharmacology; 2022 Nov; 218():109205. PubMed ID: 35940348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
    Buck K; Voehringer P; Ferger B
    J Neurochem; 2010 Jan; 112(2):444-52. PubMed ID: 19895663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphologic changes of dendritic spines of striatal neurons in the levodopa-induced dyskinesia model.
    Nishijima H; Suzuki S; Kon T; Funamizu Y; Ueno T; Haga R; Suzuki C; Arai A; Kimura T; Suzuki C; Meguro R; Miki Y; Yamada J; Migita K; Ichinohe N; Ueno S; Baba M; Tomiyama M
    Mov Disord; 2014 Mar; 29(3):336-43. PubMed ID: 24573720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synaptic dysfunction in Parkinson's disease.
    Bagetta V; Ghiglieri V; Sgobio C; Calabresi P; Picconi B
    Biochem Soc Trans; 2010 Apr; 38(2):493-7. PubMed ID: 20298209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Cenci MA
    Amino Acids; 2002; 23(1-3):105-9. PubMed ID: 12373525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Fox SH; Henry B; Hill M; Crossman A; Brotchie J
    Mov Disord; 2002 Nov; 17(6):1180-7. PubMed ID: 12465055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.